Harmony Biosciences Holdings, Inc. (HRMY) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $31.74 (+1.54%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 11, 2026 | Youn Shim | UBS | $46.00 | +44.9% |
| Nov 24, 2025 | Andreas Argyrides | Oppenheimer | $62.00 | +95.3% |
| Jul 10, 2025 | Corinne Johnson | Goldman Sachs | $33.00 | +4.0% |
| Oct 30, 2024 | Corinne Jenkins | Goldman Sachs | $28.00 | -11.8% |
| Oct 10, 2024 | Graig Suvannavejh | Mizuho Securities | $52.00 | +63.8% |
| Sep 10, 2024 | Ashwani Verma | UBS | $56.00 | +76.4% |
| Aug 8, 2024 | Graig Suvannavejh | Mizuho Securities | $42.00 | +32.3% |
| Jun 24, 2024 | Francois Brisebois | Oppenheimer | $56.00 | +76.4% |
| May 1, 2024 | Ami Fadia | Needham | $52.00 | +63.8% |
| Apr 30, 2024 | Danielle Brill | Raymond James | $37.00 | +16.6% |
| Oct 14, 2022 | Chris Howerton | Jefferies | $61.00 | +92.2% |
Top Analysts Covering HRMY
HRMY vs Sector & Market
| Metric | HRMY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.40 | 2.24 | 2.41 |
| Analyst Count | 10 | 8 | 18 |
| Target Upside | +47.5% | +1150.2% | +14.9% |
| P/E Ratio | 11.71 | 6.86 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $244M | $246M | $250M | 6 |
| 2026-09-30 | $257M | $267M | $276M | 4 |
| 2026-12-31 | $270M | $282M | $290M | 5 |
| 2027-03-31 | $250M | $261M | $269M | 3 |
| 2027-06-30 | $277M | $288M | $297M | 3 |
| 2027-09-30 | $302M | $314M | $324M | 3 |
| 2027-12-31 | $321M | $335M | $345M | 3 |
| 2028-12-31 | $1.22B | $1.22B | $1.22B | 9 |
| 2029-12-31 | $1.14B | $1.27B | $1.35B | 4 |
| 2030-12-31 | $955M | $1.06B | $1.13B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.88 | $0.89 | $0.90 | 3 |
| 2026-09-30 | $0.93 | $0.98 | $1.02 | 1 |
| 2026-12-31 | $0.97 | $1.02 | $1.06 | 1 |
| 2027-03-31 | $0.81 | $0.85 | $0.89 | 1 |
| 2027-06-30 | $0.96 | $1.01 | $1.06 | 1 |
| 2027-09-30 | $0.98 | $1.03 | $1.07 | 1 |
| 2027-12-31 | $1.12 | $1.19 | $1.23 | 1 |
| 2028-12-31 | $1.45 | $4.89 | $6.48 | 9 |
| 2029-12-31 | $4.50 | $5.19 | $5.62 | 3 |
| 2030-12-31 | $3.93 | $4.54 | $4.91 | 3 |
Frequently Asked Questions
What is the analyst consensus for HRMY?
The consensus among 10 analysts covering Harmony Biosciences Holdings, Inc. (HRMY) is Buy with an average price target of $48.17.
What is the highest price target for HRMY?
The highest price target for HRMY is $62.00, set by Andreas Argyrides at Oppenheimer on 2025-11-24.
What is the lowest price target for HRMY?
The lowest price target for HRMY is $28.00, set by Corinne Jenkins at Goldman Sachs on 2024-10-30.
How many analysts cover HRMY?
10 analysts have issued ratings for Harmony Biosciences Holdings, Inc. in the past 12 months.
Is HRMY a buy or sell right now?
Based on 10 analyst ratings, HRMY has a consensus rating of Buy (2.40/5) with a +47.5% upside to the consensus target of $48.17.
What are the earnings estimates for HRMY?
Analysts estimate HRMY will report EPS of $0.89 for the period ending 2026-06-30, with revenue estimated at $246M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.